T-cell-dependent antibody responses in the rat: Forms and sources of keyhole limpet hemocyanin matter

References

• Descotes, J. 2009. Immunotoxicity of monoclonal antibodies. MAbs. 1:104–111
   PubMed Web of Science ®Google Scholar
• FDA. 2002. Guidance for industry: Immunotoxicology Evaluation of Investigational New Drugs. Bethesda, MD
   Google Scholar
• Feinberg, H., Mitchell, D. A., Drickamer, K., and Weis, W. I. 2001. Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science 294:2163–2166
   PubMed Web of Science ®Google Scholar
• Figdor, C. G., van Kooyk, Y., and Adema, G. J. 2002. C-Type lectin receptors on dendritic cells and Langerhans cells. Nat. Rev. Immunol. 2:77–84
   PubMed Web of Science ®Google Scholar
• Gringhuis, S. I., den Dunnen, J., Litjens, M., et al. 2009. Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori. Nat. Immunol. 10:1081–1088
   PubMed Web of Science ®Google Scholar
• Guide for the Care and Use of Laboratory Animals, 8th Edition, 2011. National Academic Press, Washington DC
   Google Scholar
• Guy-Grand, D., Griscelli, C., and Vassalli, P. 1974. The gut-associated lymphoid system: Nature and properties of the large dividing cells. Eur. J. Immunol. 4:435–443
   PubMed Web of Science ®Google Scholar
• Harris, J. R., Gebauer, W., Sohngen, S. M., et al. 1997. Keyhole limpet hemocyanin (KLH), II: Characteristic reassociation properties of purified KLH1 and KLH2. Micron. 28:43–56
   PubMed Web of Science ®Google Scholar
• Herscowitz, H. B., Harold, W. W., and Stavitsky, A. B. 1972. Immunochemical and immunogenic properties of a purified keyhold limpet haemocyanin. Immunology 22:51–61
   PubMed Web of Science ®Google Scholar
• ICH. 2005. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline S8. Immunotoxicity Studies for Human Pharmaceuticals
   Google Scholar
• Jain, S., O’Hagan, D. T., and Singh, M. 2011. The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant. Expert Rev. Vaccines 10:1731–1742
   PubMed Web of Science ®Google Scholar
• Joubert, M. K., Hokom, M., Eakin, C., et al. 2012. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J. Biol. Chem. 287:25266–25279
   PubMed Web of Science ®Google Scholar
• Kantele, A., Zivny, J., Hakkinen, M., et al. 1999. Differential homing commitments of antigen-specific T-cells after oral or parenteral immunization in humans. J. Immunol. 162:5173–5177
   PubMed Web of Science ®Google Scholar
• Kantelhardt, S. R., Wuhrer, M., Dennis, R. D., et al. 2002. Fuc(α1→3)GalNAc-: The major antigenic motif of Schistosoma mansoni glycolipids implicated in infection sera and keyhole-limpet haemocyanin cross-reactivity. Biochem. J. 366:217–223
   PubMed Web of Science ®Google Scholar
• Kim, C. J., Berlin, J. A., Bugelski, P. J., et al. 2007. Combined analyses of heterogeneous immunotoxicology studies using functional T-cell-dependent antibody response tests. Perspect. Exp. Clin. Immunotoxicol. 1:61–76
   Google Scholar
• Mann, J. F., Shakir, E., Carter, K. C., et al. 2009. Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the TH1/TH2 bias in the immune response and protection against infection. Vaccine 27:3643–3649
   PubMed Web of Science ®Google Scholar
• Manocha, M., Pal, P. C., Chitralekha, K. T., et al. 2005. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target. Vaccine 23:5599–5617
   PubMed Web of Science ®Google Scholar
• McDermott, M. R., Horsewood, P., Clark, D. A., and Bienenstock, J. 1986. T-Lymphocytes in the intestinal epithelium and lamina propria of mice. Immunology. 57:213–218
   PubMed Web of Science ®Google Scholar
• Men, Y., Gander, B., Merkle, H. P., and Corradin, G. 1996. Induction of sustained and elevated immune responses to weakly immunogenic synthetic malarial peptides by encapsulation in biodegradable polymer microspheres. Vaccine 14:1442–1450
   PubMed Web of Science ®Google Scholar
• Miller, J. S., Curtsinger, J., Berthold, M., et al. 2005. Diminished neo-antigen response to keyhole limpet hemocyanin (KLH) vaccines in patients after treatment with chemotherapy or hematopoietic cell transplantation. Clin. Immunol. 117:144–151
   PubMed Web of Science ®Google Scholar
• Presicce, P., Taddeo, A., Conti, A., et al. 2008. Keyhole limpet hemocyanin induces the activation and maturation of human dendritic cells through the involvement of mannose receptor. Mol. Immunol. 45:1136–1145
   PubMed Web of Science ®Google Scholar
• Swerdlow, R. D., Ebert, R. F., Lee, P., et al. 1996. Keyhole limpet hemocyanin: Structural and functional characterization of two different subunits and multimers. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 113:537–548
   PubMed Web of Science ®Google Scholar
• Weigle, W. O. 1964. Immunochemical properties of hemocyanin. Immunochemistry 1:295–302
   PubMedGoogle Scholar
• Wirguin, I., Suturkova-Milosevic, L., Briani, C., and Latov, N. 1995. Keyhole limpet hemocyanin contains Gal(β 1-3)-GalNAc determinants that are cross-reactive with the T-antigen. Cancer Immunol. Immunother. 40:307–310
   PubMed Web of Science ®Google Scholar
• Wuhrer, M., Robijn, M. L., Koeleman, C. A., et al. 2004. A novel Gal(β1-4)Gal(β1-4)Fuc(α1-6)-core modification attached to the proximal N-acetylglucosamine of keyhole limpet haemocyanin (KLH) N-glycans. Biochem. J. 378:625–632
   PubMed Web of Science ®Google Scholar
• Yefenof, E., Zehavi-Feferman, R., and Guy, R. 1990. Control of primary and secondary antibody responses by cytotoxic T-lymphocytes specific for a soluble antigen. Eur. J. Immunol. 20:1849–1853
   PubMed Web of Science ®Google Scholar